AR117616A1 - Compuestos anti-vih - Google Patents
Compuestos anti-vihInfo
- Publication number
- AR117616A1 AR117616A1 ARP190102044A ARP190102044A AR117616A1 AR 117616 A1 AR117616 A1 AR 117616A1 AR P190102044 A ARP190102044 A AR P190102044A AR P190102044 A ARP190102044 A AR P190102044A AR 117616 A1 AR117616 A1 AR 117616A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- membered
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000036436 anti-hiv Effects 0.000 title 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 19
- 125000000623 heterocyclic group Chemical group 0.000 abstract 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 14
- 125000005842 heteroatom Chemical group 0.000 abstract 14
- 229910052760 oxygen Inorganic materials 0.000 abstract 14
- 229910052717 sulfur Inorganic materials 0.000 abstract 14
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- -1 N (Re) 2 Chemical group 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente proporciona compuestos que tienen la fórmula (1) o una sal farmacéuticamente aceptable del mismo, así como composiciones farmacéuticas que comprenden los mismos, procesos para su preparación, y métodos de tratamiento y prevención de la infección por VIH mediante su administración. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: R¹ es un heterociclo de 5 a 10 miembros que tiene 1 a 5 heteroátomos seleccionados de N, O y S, o un heteroarilo de 5 a 10 miembros que tiene 1 a 5 heteroátomos seleccionados de N, O y S, en donde el heterociclo de 5 a 10 miembros o el heteroarilo de 5 a 10 miembros está opcionalmente sustituido con 1 a 5 grupos Rᵃ; R² y R³ son cada uno independientemente alquilo C₁₋₄, cicloalquilo C₃₋₆, O-R²A, alquilo C₁₋₂-O-R²A, N-(R³A)₂, o alquilo C₁₋₂-N-(R³A)₂, en donde cada R²A es independientemente alquilo C₁₋₄, cicloalquilo C₃₋₆, o un heterociclilo de 4 a 10 miembros que tiene 1 a 5 heteroátomos seleccionados de N, O y S, en donde cada R³A es independientemente hidrógeno, alquilo C₁₋₄, cicloalquilo C₃₋₆, o COO(Rᵉ), en donde cada Rᵉ es independientemente hidrógeno o alquilo C₁₋₄, y en donde cada cicloalquilo C₃₋₆ o heterociclilo de 4 a 10 miembros está opcionalmente sustituido por 1 a 3 grupos Rᶠ, en donde cada Rᶠ es independientemente alquilo C₁₋₂ o halógeno; R⁴ es hidrógeno, halo, alquilo C₁₋₄, haloalquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, o haloalcoxi C₁₋₄; R⁷ es hidrógeno, halo, alquilo C₁₋₄, haloalquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, o haloalcoxi C₁₋₄; R⁵, R⁶, R⁸, y R⁹ son cada uno independientemente hidrógeno, halo, alquilo C₁₋₂, haloalquilo C₁₋₂, o cicloalquilo C₃₋₆; y en donde dos o más R⁴, R⁵ y R⁶ o dos o más de R⁷, R⁸, y R⁹ opcionalmente se unen para formar uno o más grupos cicloalquilo C₃₋₆ que están opcionalmente sustituidos con 1 a 4 grupos seleccionados de halógeno, alquilo C₁₋₂, y haloalquilo C₁₋₂; cada R¹⁰ es independientemente halógeno, ciano, alcoxi C₁₋₄, alquilo C₁₋₆, o cicloalquilo C₃₋₆; n es 0 a 4; cada Rᵃ es independientemente halógeno, alquilo C₁₋₄, alquilo C₁₋₄ con uno o dos grupos seleccionados de hidroxilo y alcoxi C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, cicloalquilo C₃₋₆, heterociclilo de 4 a 10 miembros que tiene 1 a 5 heteroátomos seleccionados de N, O y S el cual está opcionalmente sustituido con Rᵃ¹, o O-R³B, en donde R³B es cicloalquilo C₃₋₆ opcionalmente sustituido con Rᵃ¹ o un heterociclilo de 4 a 10 miembros que tiene 1 a 5 heteroátomos seleccionados de N, O y S opcionalmente sustituido con Rᵃ¹, en donde cada Rᵃ¹ es independientemente alquilo C₁₋₄, cicloalquilo C₃₋₆, haloalquilo C₁₋₄, o heterociclilo de 4 a 8 miembros que tiene 1 a 3 heteroátomos seleccionados de N, O y S; A es etinilo o un enlace; X¹ es un arilo de 6 a 10 miembros o un heteroarilo de 5 a 10 miembros que tiene 1 a 3 heteroátomos seleccionados de N, O y S, en donde cada arilo de 6 a 10 miembros o el heteroarilo de 5 a 10 miembros está opcionalmente sustituido con 1 a 4 grupos Rᵇ; X² es hidrógeno o un heterociclilo de 4 a 10 miembros que tiene 1 a 5 heteroátomos seleccionados de N, O y S, en donde el heterociclilo de 4 a 10 miembros está opcionalmente sustituido con un R¹¹ y opcionalmente sustituido con 1 a 5 grupos Rᵇ; R¹¹ es -C=O(Rᶜ), CH₂(Rᵈ), S(O)₁₋₂(C₁₋₄ alquilo), S(O)₁₋₂-(cicloalquilo C₃₋₆), un heterociclilo de 4 a 10 miembros que tiene 1 a 5 heteroátomos seleccionados de N, O y S, o un heteroarilo de 5 a 9 miembros que tiene 1 a 5 heteroátomos seleccionados de N, O y S, en donde cada heterociclilo de 4 a 10 miembros o heteroarilo de 5 a 9 miembros está opcionalmente sustituido con 1 a 5 grupos Rᵇ; cada Rᵇ es independientemente halógeno, oxo, alquilo C₁₋₄, alquilo C₁₋₄ con uno o dos grupos seleccionados de hidroxilo y alcoxi C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, o COO(Rᶜ); Rᶜ es alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, N(Rᵉ)₂, cicloalquilo C₃₋₆, o un heterociclilo de 4 a 6 miembros que tiene 1 a 3 heteroátomos seleccionados de N, O y S, en donde el cicloalquilo C₃₋₆ y el heterociclilo de 4 a 6 miembros están opcionalmente sustituidos por 1 a 5 grupos Rᵇ; Rᵈ es COO(Rᵉ), N(Rᵉ)₂, cicloalquilo C₃₋₆, o un heterociclilo de 4 a 6 miembros que tiene 1 a 3 heteroátomos seleccionados de N, O y S, en donde cicloalquilo C₃₋₆ y el heterociclilo de 4 a 6 miembros está opcionalmente sustituido por 1 a 5 grupos Rᵇ; cada R¹² es alquilo C₁₋₂, halo, -O-alquilo C₁₋₂, o ciano, cada p es 0 a 4; R¹³ es -C(=O)Rᵍ¹, -C(=O)ORᵍ², o -P(=O)(ORʰ)₂; Rᵍ¹ es H, alquilo C₁₋₆, cicloalquilo C₃₋₆, o heteroarilo de 5 a 6 miembros que tiene 1 a 3 heteroátomos seleccionados de N, O y S; en donde el alquilo C₁₋₆ de Rᵍ¹ está opcionalmente sustituido con 1, 2, 3, ó 4 sustituyentes seleccionados independientemente de halógeno, alcoxi C₁₋₄, -N(Rⁱ)₂, -alquilo C₁₋₄-N(Rⁱ)₂, -N(Rⁱ)₃⁺, y heterociclilo de 4 a 6 miembros que tiene 1 a 3 heteroátomos seleccionados de N, O y S, en donde el heterociclilo de 4 a 6 miembros está opcionalmente sustituido con 1, 2, 3 ó 4 sustituyentes seleccionados independientemente de halógeno, alquilo C₁₋₄, alcoxi C₁₋₄, -N(Rⁱ)₂, y -alquilo C₁₋₄-N(Rⁱ)₂; en donde el heteroarilo de 5 a 6 miembros y cicloalquilo C₃₋₆ de Rᵍ¹ están cada uno opcionalmente sustituidos con 1, 2, 3 ó 4 sustituyentes seleccionados independientemente de halógeno, alquilo C₁₋₆, alcoxi C₁₋₄, -N(Rⁱ)₂, y -alquilo C₁₋₄-N(Rⁱ)₂; Rᵍ² es alquilo C₁₋₆ opcionalmente sustituido con 1, 2, 3 ó 4 sustituyentes seleccionados independientemente de halógeno, alquilo C₁₋₆, alcoxi C₁₋₄, -N(Rⁱ)₂, -alquilo C₁₋₄-N(Rⁱ)₂, y -O-P(=O)(ORʰ)₂; y Rʰ y Rⁱ son cada uno seleccionados independientemente de H y alquilo C₁₋₃.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711768P | 2018-07-30 | 2018-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117616A1 true AR117616A1 (es) | 2021-08-18 |
Family
ID=67551748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102044A AR117616A1 (es) | 2018-07-30 | 2019-07-19 | Compuestos anti-vih |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11052087B2 (es) |
| EP (1) | EP3829588A1 (es) |
| JP (2) | JP7147042B2 (es) |
| KR (1) | KR102583013B1 (es) |
| CN (1) | CN112533609B (es) |
| AR (1) | AR117616A1 (es) |
| AU (2) | AU2019314282C1 (es) |
| CA (1) | CA3103157C (es) |
| TW (2) | TWI829205B (es) |
| WO (1) | WO2020028272A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| HUE059677T2 (hu) | 2019-03-22 | 2022-12-28 | Gilead Sciences Inc | Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása |
| CN113304166B (zh) * | 2020-02-27 | 2022-10-14 | 河南真实生物科技有限公司 | 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| SI4244396T1 (sl) | 2020-11-11 | 2025-10-30 | Gilead Sciences, Inc. | Postopki za prepoznavanje pacientov s hiv, ki so občutljivi na terapijo s protitelesi, usmerjenimi proti vezavnemu mestu cd4 od gp120 |
| FI4440702T3 (fi) | 2021-12-03 | 2025-08-08 | Gilead Sciences Inc | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於ｈｉｖ病毒感染之治療性化合物 |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| WO2024220624A1 (en) | 2023-04-19 | 2024-10-24 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| AU2024283382A1 (en) * | 2023-05-31 | 2025-11-13 | Gilead Sciences, Inc. | Anti-hiv compounds |
| AU2024281548A1 (en) | 2023-05-31 | 2025-11-13 | Gilead Sciences, Inc. | Solid forms of compounds useful in the treatment of hiv |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202530226A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250120989A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250326779A1 (en) * | 2024-04-03 | 2025-10-23 | Gilead Sciences, Inc. | Anti-hiv compounds |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5753652A (en) | 1991-07-03 | 1998-05-19 | Novartis Corporation | Antiretroviral hydrazine derivatives |
| ES2093237T3 (es) | 1991-07-03 | 1996-12-16 | Ciba Geigy Ag | Derivados de hidrazina farmacologicamente activos y procedimiento para su obtencion. |
| AU2003200066B9 (en) | 1992-03-11 | 2007-02-15 | Narhex Limited | Amine Derivatives of Oxo- and Hydroxy-substituted Hydrocarbons |
| EP0633881B1 (en) | 1992-03-11 | 2003-10-29 | Narhex Limited | Amine derivatives of oxo- and hydroxy-substitued hydrocarbons |
| DE59303870D1 (de) | 1992-12-23 | 1996-10-24 | Ciba Geigy Ag | Antiretrovirale hydrazinderivate |
| US5461067A (en) | 1993-02-25 | 1995-10-24 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| DE69621651T2 (de) | 1995-11-21 | 2002-11-21 | Novartis Ag, Basel | Azahexan-derivate als substratisostere von retroviralen aspartat-proteasen |
| TW409125B (en) | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
| US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| AU2959397A (en) | 1996-05-31 | 1998-01-05 | Novartis Ag | Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues |
| EP0915841B1 (en) | 1996-07-17 | 2002-02-27 | Novartis AG | Anilinopeptide derivatives |
| CH694251A5 (de) | 1999-07-14 | 2004-10-15 | Eprova Ag | Herstellung von Tetrahydropterin und Derivaten. |
| EP2314564A3 (en) | 1999-12-23 | 2012-04-04 | Ampac Fine Chemicals LLC | Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
| CA2448084A1 (en) | 2001-05-22 | 2002-11-28 | Elan Pharmaceuticals, Inc. | Aza hydroxylated ethyl amine compounds |
| CA2483959A1 (en) | 2001-08-28 | 2003-03-13 | Elan Pharmaceuticals, Inc. | Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons |
| US7157489B2 (en) | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
| CA2523083C (en) | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| EP1697348B1 (en) | 2003-12-11 | 2011-12-28 | Abbott Laboratories | Hiv protease inhibiting compounds |
| CN101023090B (zh) | 2004-07-06 | 2013-03-27 | 雅培制药有限公司 | Hiv蛋白酶抑制剂的前药 |
| AP2412A (en) | 2004-07-27 | 2012-06-01 | Gilead Sciences Inc | Phosphonate analogs of HIV inhibitor compounds. |
| CA2667445A1 (en) | 2005-06-22 | 2007-01-04 | University Of Massachusetts | Hiv-1 protease inhibitors |
| CA2657821A1 (en) | 2006-07-21 | 2008-01-24 | Gilead Sciences, Inc. | Aza-peptide protease inhibitors |
| JP5599611B2 (ja) | 2006-07-21 | 2014-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルスプロテアーゼインヒビター |
| CN101702908A (zh) | 2007-03-23 | 2010-05-05 | 麻萨诸塞州大学 | Hiv-1蛋白酶抑制剂 |
| RS51226B (sr) | 2007-06-12 | 2010-12-31 | Concert Pharmaceuticals Inc. | Derivati azapeptida kao inhibitori hiv proteaze |
| US20090076097A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched atazanavir |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| EP2262538B1 (en) | 2008-03-12 | 2014-12-10 | Nektar Therapeutics | Oligomer-amino acid conjugate |
| US20110178305A1 (en) | 2008-05-08 | 2011-07-21 | Ranbaxy Laboratories Limited | Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof |
| TWI466735B (zh) | 2008-09-18 | 2015-01-01 | 傑士湯淺國際股份有限公司 | 紫外線照射裝置 |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| WO2010077317A2 (en) | 2008-12-17 | 2010-07-08 | Amplyx Pharmaceuticals, Inc. | Protease inhibitors |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| EP2440249A2 (en) | 2009-06-12 | 2012-04-18 | Nektar Therapeutics | Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety |
| EP2292589A1 (en) | 2009-09-02 | 2011-03-09 | IMTM GmbH | Novel multifunctional peptidase inhibitors, especially for medical use |
| WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
| NZ604716A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| US8563597B2 (en) | 2010-09-02 | 2013-10-22 | Purdue Research Foundation | Fused tricyclic ether carbamates and their use |
| WO2012092168A1 (en) | 2010-12-27 | 2012-07-05 | Purdue Research Foundation | Fused 6,5 bicyclic ring system p2 ligands, and methods for treating hiv |
| US9024038B2 (en) | 2010-12-27 | 2015-05-05 | Purdue Research Foundation | Compunds and methods for treating HIV |
| WO2012092188A1 (en) | 2010-12-27 | 2012-07-05 | Ghosh Arun K | Hydrogen bond forming p1 ligands and methods for treating hiv |
| US9006229B2 (en) | 2011-04-21 | 2015-04-14 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| WO2012170792A1 (en) | 2011-06-10 | 2012-12-13 | Concert Pharmaceuticals, Inc. | Atazanavir metabolite derivatives |
| CA2840095A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
| RU2014115227A (ru) | 2012-04-20 | 2015-10-27 | Джилид Сайэнс, Инк. | Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции |
| PT3067358T (pt) | 2012-12-21 | 2019-11-18 | Gilead Sciences Inc | Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica |
| RU2015131006A (ru) | 2012-12-27 | 2017-01-30 | Джапан Тобакко Инк. | ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ) |
| WO2015097667A2 (en) | 2013-12-23 | 2015-07-02 | Cellworks Group, Inc., | A composition, process of preparation of said composition, kit and a method of treating cancer |
| DK3142659T3 (da) | 2014-05-16 | 2021-05-31 | Purdue Research Foundation | Hiv-1 proteasehæmmere og anvendelser deraf |
| ES2695700T3 (es) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirales |
| JOP20180009A1 (ar) * | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
-
2019
- 2019-07-09 TW TW111123041A patent/TWI829205B/zh active
- 2019-07-09 TW TW108124043A patent/TWI766172B/zh active
- 2019-07-19 AR ARP190102044A patent/AR117616A1/es unknown
- 2019-07-29 CA CA3103157A patent/CA3103157C/en active Active
- 2019-07-29 KR KR1020217005603A patent/KR102583013B1/ko active Active
- 2019-07-29 AU AU2019314282A patent/AU2019314282C1/en active Active
- 2019-07-29 JP JP2021504759A patent/JP7147042B2/ja active Active
- 2019-07-29 WO PCT/US2019/043965 patent/WO2020028272A1/en not_active Ceased
- 2019-07-29 EP EP19752359.0A patent/EP3829588A1/en active Pending
- 2019-07-29 CN CN201980050838.2A patent/CN112533609B/zh active Active
- 2019-07-29 US US16/525,203 patent/US11052087B2/en active Active
-
2022
- 2022-07-19 JP JP2022114883A patent/JP2022137268A/ja not_active Withdrawn
- 2022-10-19 AU AU2022256119A patent/AU2022256119A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11052087B2 (en) | 2021-07-06 |
| JP2022137268A (ja) | 2022-09-21 |
| AU2022256119A1 (en) | 2022-12-01 |
| US20200030327A1 (en) | 2020-01-30 |
| TW202019423A (zh) | 2020-06-01 |
| KR20210038621A (ko) | 2021-04-07 |
| CN112533609A (zh) | 2021-03-19 |
| CA3103157C (en) | 2023-09-26 |
| AU2019314282A1 (en) | 2021-01-28 |
| TWI829205B (zh) | 2024-01-11 |
| KR102583013B1 (ko) | 2023-09-27 |
| JP7147042B2 (ja) | 2022-10-04 |
| TWI766172B (zh) | 2022-06-01 |
| EP3829588A1 (en) | 2021-06-09 |
| AU2019314282B2 (en) | 2022-07-21 |
| WO2020028272A1 (en) | 2020-02-06 |
| CA3103157A1 (en) | 2020-02-06 |
| CN112533609B (zh) | 2024-07-09 |
| AU2019314282C1 (en) | 2023-02-16 |
| TW202313622A (zh) | 2023-04-01 |
| JP2021532154A (ja) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117616A1 (es) | Compuestos anti-vih | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR099788A1 (es) | Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih | |
| AR105875A1 (es) | Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR108396A1 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR089285A1 (es) | Derivados de betulina | |
| AR096332A1 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih | |
| AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR123648A1 (es) | Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos | |
| AR116392A1 (es) | Compuestos de fenoxi-piridil-pirimidina y métodos de uso | |
| AR101561A1 (es) | Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona | |
| AR111271A1 (es) | Inhibidores dobles de magl y faah | |
| AR104512A1 (es) | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
| AR098723A1 (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco |